Advertisement
Australia markets closed

  • ALL ORDS

    7,897.50
    +48.10 (+0.61%)
     

  • ASX 200

    7,629.00
    +42.00 (+0.55%)
     

  • AUD/USD

    0.6612
    +0.0040 (+0.61%)
     

  • OIL

    77.99
    -0.96 (-1.22%)
     

  • GOLD

    2,310.10
    +0.50 (+0.02%)
     

  • Bitcoin AUD

    95,134.66
    +4,891.49 (+5.42%)
     

  • CMC Crypto 200

    1,359.39
    +82.41 (+6.45%)
     

  • AUD/EUR

    0.6140
    +0.0020 (+0.33%)
     

  • AUD/NZD

    1.0992
    -0.0017 (-0.16%)
     

  • NZX 50

    11,938.08
    +64.04 (+0.54%)
     

  • NASDAQ

    17,890.79
    +349.25 (+1.99%)
     

  • FTSE

    8,213.49
    +41.34 (+0.51%)
     

  • Dow Jones

    38,675.68
    +450.02 (+1.18%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • Hang Seng

    18,475.92
    +268.79 (+1.48%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

Is BioTelemetry (BEAT) Outperforming Other Medical Stocks This Year?

Zacks
Is (CRM) Outperforming Other Computer and Technology Stocks This Year?

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. BioTelemetry (BEAT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

BioTelemetry is a member of our Medical group, which includes 841 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. BEAT is currently sporting a Zacks Rank of #1 (Strong Buy).

The Zacks Consensus Estimate for BEAT's full-year earnings has moved 19.74% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

ADVERTISEMENT

Based on the most recent data, BEAT has returned 118.36% so far this year. In comparison, Medical companies have returned an average of 1.12%. As we can see, BioTelemetry is performing better than its sector in the calendar year.

Breaking things down more, BEAT is a member of the Medical Services industry, which includes 34 individual companies and currently sits at #81 in the Zacks Industry Rank. On average, this group has gained an average of 24.61% so far this year, meaning that BEAT is performing better in terms of year-to-date returns.

BEAT will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
BioTelemetry, Inc. (BEAT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.